Contributions of Costimulatory Molecule CD137 in Endothelial Cells.
Wei Yuan,Chong Xu,Bo Li,Hao Xia,Yingjie Pan,Wei Zhong,Liangjie Xu,Rui Chen,Bin Wang
DOI: https://doi.org/10.1161/jaha.120.020721
IF: 6.106
2021-05-26
Journal of the American Heart Association
Abstract:CD137 (4‐1BB, tumor necrosis factor receptor superfamily 9) is a surface glycoprotein of the tumor necrosis factor receptor family that can be induced on a variety of immunocytes and nonimmune cells, including endothelial cells and smooth muscle cells. The importance of CD137 in immune response has been well recognized; however, the precise biological effects and underlying mechanisms of CD137 in endothelial cells are unclear. A single layer of cells called the endothelium constitutes the innermost layer of blood vessels including larger arteries, veins, the capillaries, and the lymphatic vessels. It not only acts as an important functional interface, but also participates in local inflammatory response. This review covers recent findings to illuminate the role of CD137 in endothelial cells in different pathophysiologic settings. Nonstandard Abbreviations and Acronyms CRDs cysteine‐rich domains DCs dendritic cells ECs endothelial cells EV extracellular vesicle mAbs monoclonal antibodies SMCs smooth muscle cells TECs tumor ECs TET2 ten‐eleven translocation protein methylcytosine dioxygenase 2 TME tumor microenvironment TRAF tumor necrosis factor (TNF) receptor‐associated factor Tumor necrosis factor superfamily and tumor necrosis factor receptor superfamily are important cellular signaling pathways involved in apoptosis, inflammation, tissue development, and lymphocyte homeostasis, such as CD137/CD137L, OX40/OX40L, CD40/CD40L, and Fas‐FasL. The interaction between CD137 and CD137L (its ligand) is the second signal for activating T lymphocytes and is involved in cellular immune responses, immune tolerance, and other reactions. CD137 has been found to be expressed not only in immune cells, but also in vascular cells. CD137‐positive blood vessels have been identified in atherosclerotic lesions, tumors, and vasculitis. 1 CD137 is mainly expressed by activated endothelial cells (ECs) and smooth muscle cells (SMCs). Notably, ECs are the primary component of the endothelial lining of the circulatory system (blood and lymph), which are considered major participants in and regulators of inflammatory reactions. Endothelial dysfunction induced by the activation of CD137 signaling effectively induces a state of inflammation, which plays a critical role in a variety of pathological conditions. Currently, excellent reviews are available on the role of CD137 in the immune system and immunotherapy. 2 , 3 In this article, a review of the literatures focusing on the evidence of the implication of CD137 in the biological effects of ECs was conducted on PubMed and Google Scholar. Search Strategy Our literature search was performed in PubMed and Google Scholar with no language limitation. The search strategy involved combining the following keywords: CD137, 4‐1BB, CD137L, 4‐1BBL, ECs, endothelium, inflammation, vascular, and vessel . Publications should be between January 1990 to September 2020, including various types of CD137 and endothelium‐related articles. Structure and Regulation of CD137 CD137 is a type I transmembrane glycoprotein receptor characterized by the presence of cysteine‐rich domains. As in most of the tumor necrosis factor receptor superfamily members, CD137 exists in a membrane‐bound, soluble form. Although some studies have shown that CD137 exists as a monomer and dimer, it has recently been suggested that CD137 is a functional trimer complex that exists on cell surfaces. It has also been confirmed that CD137 is predominantly expressed in most immune cells, including activated CD4 + and CD8 + T cells, natural killer cells, natural killer T (natural killer T cell) cells, and CD4 + CD25 + regulatory T cells. CD137 is also expresse -Abstract Truncated-
cardiac & cardiovascular systems